Antagonist effect of a receptor-mimicking peptide encoded by human angiotensin II complementary RNA.
This article reports on the binding and the angiotensin II (Ang II) antagonistic properties of a peptide, referred to as hIIA, encoded by an RNA strand complementary to the human Ang II messenger RNA. Although Ang II and hIIA (H2N-Glu-Gly-Val-Tyr-Val-His-Pro-Val-COOH) share four amino acids, the iodinated and tritiated forms of hIIA were unreactive with seven monoclonal antibodies defining four distinct epitopes on the Ang II molecule and failed to bind to Ang II hepatic and mesangial receptors. However, hIIA did inhibit binding of 125I-Ang II to rat hepatocyte membranes (IC50, 2 x 10(-7) M) and to the various monoclonal antibodies. The lowest IC50 (5 x 10(-7) M) was measured with the monoclonal antibody specific for the Ang II sequence generally considered as implicated in receptor recognition. As predicted from the binding studies, hIIA was further shown to antagonize some biological properties of Ang II. On mesangial cells, hIIA alone had no effect on intracellular calcium concentration ([Ca2+]i) and prostaglandin E2 synthesis but did abolish the transient increase in [Ca2+]i in response to 100 nM Ang II and did induce a specific dose-dependent inhibition of the Ang II-stimulated prostaglandin E2 release. Furthermore, intravenous infusion of hIIA (200 micrograms.kg-1.min-1) inhibited by 66 +/- 3% the rat hypertensive response to 100 ng.kg-1 Ang II but had no effect on the pressor activity of agents such as alpha 1-adrenergic and HT2 serotonin agonists. Our data suggest that the "complementary" peptide hIIA interacts directly with Ang II by mimicking the Ang II complementary site on the receptor and can inhibit the physiological effects of Ang II. This type of Ang II complementary peptide may serve as a model for a new class of antihypertensive drugs.
Budisavljevic
M
M
Institut National de la Santé et de la Recherche Médicale U.64, Hôpital Tenon, Paris, France.
Béa
M L
ML
Bensoussan
M
M
Laubie
M
M
Van Chuong
P P
PP
Dussaule
J C
JC
Verroust
P J
PJ
Ronco
P M
PM
D000595:Amino Acid Sequence; D000804:Angiotensin II / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000235:genetics; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism; D001483:Base Sequence; D002118:Calcium / Q000378:metabolism; D015232:Dinoprostone / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D006973:Hypertension / Q000139:chemically induced / Q000517:prevention & control; D008297:Male; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D012333:RNA, Messenger / Q000737:chemistry*; D051381:Rats; D011919:Rats, Inbred Strains; D011945:Receptors, Angiotensin / Q000378:metabolism
D057911:Angiotensin Receptor Antagonists; D000911:Antibodies, Monoclonal; D009842:Oligopeptides; D012333:RNA, Messenger; D011945:Receptors, Angiotensin; D000804:Angiotensin II; C073965:glutamyl-glycyl-valyl-tyrosyl-valyl-histidyl-prolyl-valine; D015232:Dinoprostone; D002118:Calcium